ESPE Yearbook of Paediatric Endocrinology

In brief: This 1-year, open-label, randomised controlled trial examined the effects and tolerability of denosumab, compared with zoledronic acid, on bone mineral density (BMD), spinal morphometry, and safety in a large cohort of children (n=84) with osteogenesis imperfecta. Treatment with denosumab increased BMD and improved spinal morphometry in children with OI, but was frequently associated with rebound hypercalcaemia (in 31%). This rebound hypercalcaemia could be alleviate...